Eu­ro­pean reg­u­la­tor rec­om­mends ap­proval of Carvyk­ti in ear­li­er lines of mul­ti­ple myelo­ma

A Eu­ro­pean Med­i­cines Agency com­mit­tee rec­om­mend­ed that the la­bel for Leg­end Biotech and John­son & John­son’s CAR-T Carvyk­ti be ex­pand­ed to mul­ti­ple myelo­ma pa­tients as a sec­ond-line op­tion, Leg­end an­nounced Fri­day morn­ing.

If rat­i­fied by Eu­ro­pean reg­u­la­tors, the ex­pand­ed la­bel could un­lock a much larg­er el­i­gi­ble pa­tient pop­u­la­tion for Carvyk­ti. The EMA’s Com­mit­tee for Med­i­c­i­nal Prod­ucts for Hu­man Use (CHMP) rec­om­mend­ed that Carvyk­ti be ap­proved for pa­tients whose mul­ti­ple myelo­ma has come back or stopped re­spond­ing to ther­a­py and who have re­ceived at least one pre­vi­ous treat­ment reg­i­men.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER